Take­da sues Apo­tex over prospec­tive gener­ic ver­sions of its top leukemia drug

Back in 2017, Take­da shelled out more than $5 bil­lion for a small­er com­pa­ny called Ari­ad Phar­ma­ceu­ti­cals, its leukemia drug Iclusig (pona­tinib) and its ALK-in­hibit­ing lung can­cer drug Alun­brig (briga­tinib).

Fast for­ward five years, and while Iclusig con­tin­ues to pull in more than $200 mil­lion per year for Take­da, the com­pa­ny is now look­ing to fend off gener­ic com­peti­tors, fil­ing suit in New Jer­sey fed­er­al court ear­li­er this week to block a com­peti­tor, Cana­da-based Apo­tex.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER